Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1α-degradative Pathway
Open accessThe DOI matches its Crossref record; 80 of the 81 references it cites were found in a registry or an index.
Abstract
HIF-1 alpha is a normally labile proangiogenic transcription factor that is stabilized and activated in hypoxia. Although the von Hippel Lindau (VHL) gene product, the ubiquitin ligase responsible for regulating HIF-1 alpha protein levels, efficiently targets HIF-1 alpha for rapid proteasome-dependent degradation under normoxia, HIF-1 alpha is resistant to the destabilizing effects of VHL under hypoxia. HIF-1 alpha also associates with the molecular chaperone Hsp90. To examine the role of Hsp90 in HIF-1 alpha function, we used renal carcinoma cell (RCC) lines that lack functional VHL and express stable HIF-1 alpha protein under normoxia. Geldanamycin (GA), an Hsp90 antagonist, promoted efficient ubiquitination and proteasome-mediated degradation of HIF-1 alpha in RCC in both normoxia and hypoxia. Furthermore, HIF-1 alpha point mutations that block VHL association did not protect HIF-1 alpha from GA-induced destabilization. Hsp90 antagonists also inhibited HIF-1 alpha transcriptional activity and dramatically reduced both hypoxia-induced accumulation of VEGF mRNA and hypoxia-dependent angiogenic activity. These findings demonstrate that disruption of Hsp90 function 1) promotes HIF-1 alpha degradation via a novel, oxygen-independent E3 ubiquitin ligase and 2) diminishes HIF-1 alpha transcriptional activity. Existence of an Hsp90-dependent pathway for elimination of HIF-1 alpha predicts that Hsp90 antagonists may be hypoxic cell sensitizers and possess antiangiogenic activity in vivo, thus extending the utility of these drugs as therapeutic anticancer agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, HSP90 inhibitors and histone acetylase inhibitors promote HIFα degradation in a pVHL-independent manner (Isaacs et al., 2002; Kong et al., 2006).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Isaacs et al., 2002
In the citing paper
“It was reported that inhibitors of Hsp90 such as geldanamycin (GA) could nullify HIF-1α levels regardless of the availability of oxygen42.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [42]
In the citing paper
“GA can induce proteasomal degradation of HIF-1α in a VHL-independent manner both under normoxic and hypoxic conditions (Isaacs et al., 2002).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Isaacs et al., 2002
In the citing paper
“Heat shock protein 90 (HSP90) stabilizes HIF-1α under hypoxia and in tumors, and pharmacological inhibition of HSP90 promotes HIF-1α destabilization [183].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [183]
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Semenza, G. L., & Wang, G. L. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5447 · Cited by 2,617
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Research works printed but not linked: 18
- Wiesener, 2001, Cancer Res., 61, 5215
- Zhong, 1999, Cancer Res., 59, 5830
- Birner, 2000, Cancer Res., 60, 4693
- Akakura, 2001, Cancer Res., 61, 6548
- Griffiths, 2002, Cancer Res., 62, 688
- Takahashi, 1994, Cancer Res., 54, 4233
- Wizigmann-Voos, 1995, Cancer Res., 55, 1358
- Whitesell, 1992, Cancer Res., 52, 1721
- Shaknovich, 1992, Mol. Cell. Biol., 12, 5059
- Hostein, 2001, Cancer Res., 61, 4003
- Nimmanapalli, 2001, Cancer Res., 61, 1799
- An, 2000, Cell Growth Differ., 11, 355
- Bonvini, 2002, Cancer Res., 62, 1559
- Adams, 1999, Cancer Res., 59, 2615
- Semenza, 1992, Mol. Cell. Biol., 12, 5447
- Hockel, 1999, Cancer Res., 59, 4525
- Mabjeesh, 2002, Cancer Res., 62, 2478
- Kruger, 2001, Clin. Cancer Res., 7, 1867
Cited by
Items 301–400 of 673
The Hypoxic Inducible Stress Response as a Target for Cancer Drug Discovery
Welsh, S. J., Koh, M. Y., & Powis, G. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.011 · Cited by 57
Mitochondrial dysfunction, UPRmt signaling, and targeted therapy in metastasis tumor
Keerthiga, R., Pei, D., & Fu, A. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00696-0 · Cited by 54
“Geldanamycin inhibits the UPR pathway’s chaperones, reduces the HIF1-α stabilization, and stimulates the hypoxic carcinoma death [135].”
BackgroundKaragiota, A., Kourti, M., Simos, G., & Mylonis, I. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2985-7 · Cited by 59
Action Sites and Clinical Application of HIF-1α Inhibitors
Xu, R., Wang, F., Yang, H., & Wang, Z. (2022) · Molecules · doi:10.3390/molecules27113426 · Cited by 71
Hu, Y., Kirito, K., Yoshida, K., Mitsumori, T., Nakajima, K., Nozaki, Y., Hamanaka, S., Nagashima, T., Kunitama, M., Sakoe, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0150 · Cited by 55
Tang, X., Chang, C., Hao, M., Chen, M., Woodley, D. T., Schönthal, A. H., & Li, W. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00316-6 · Cited by 52
Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors
Allegra, A., Sant’Antonio, E., Penna, G., Alonci, A., D’Angelo, A., Russo, S., Cannavò, A., Gerace, D. G., & Musolino, C. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01558.x · Cited by 54
THE MAIN CYTOTOXIC EFFECTS OF METHYLSELENINIC ACID ON VARIOUS CANCER CELLS
Varlamova, E. G., & Turovsky, E. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126614 · Cited by 54
Molecular Pathways for Cancer Angioprevention
Albini, A., Noonan, D. M., & Ferrari, N. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0069 · Cited by 55
Accumulation of hypoxia-inducible factor-1α is limited by transcription-dependent depletion
Demidenko, Z. N., Rapisarda, A., Garayoa, M., Giannakakou, P., Melillo, G., & Blagosklonny, M. V. (2005) · Oncogene · doi:10.1038/sj.onc.1208636 · Cited by 65
“This result indicates clinical potentials for activation of VHL-independent degradation of HIF-1a.”
BackgroundCreighton-Gutteridge, M., Cardellina, J. H., Stephen, A. G., Rapisarda, A., Uranchimeg, B., Hite, K., Denny, W. A., Shoemaker, R. H., & Melillo, G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2301 · Cited by 51
Barliya, T., Mandel, M., Livnat, T., Weinberger, D., & Lavie, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022849 · Cited by 50
“Although HIF-1a is an hsp90 client protein [15] degraded by other hsp90 inhibitors [16], the hypericin-induced HIF-1a catabolism appears to involve a unique lysosomal cathepsin-B dependent mechanism, activated in a reduced intracellular pH environment.”
BackgroundWomeldorff, M. R., Gillespie, D. L., & Jensen, R. L. (2014) · Neurosurgical FOCUS · doi:10.3171/2014.9.focus14496 · Cited by 52
Banz, V. M., Medová, M., Keogh, A., Furer, C., Zimmer, Y., Candinas, D., & Stroka, D. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2009.08.002 · Cited by 55
Hypoxia‐inducible factor 1α in oral cancer
Brennan, P. A., Mackenzie, N., & Quintero, M. (2005) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2005.00335.x · Cited by 58
Radiation sensitization with redox modulators: A promising approach
Rosenberg, A. R., & Knox, S. J. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.10.013 · Cited by 52
Targeting hypoxia and angiogenesis through HIF-1alpha inhibition
Diaz-Gonzalez, J. A., Russell, J., Rouzaut, A., Gil-Bazo, I., & Montuenga, L. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.10.2195 · Cited by 50
Godzich, M., Hodnett, M., Frank, J. A., Su, G., Pespeni, M. H., Angel, A., Howard, M., Matthay, M. A., & Pittet, J. (2006) · The FASEB Journal · doi:10.1096/fj.05-4708fje · Cited by 50
“Furthermore, Hsp90 has been shown to be a critical regulator of oxygen-independent HIF-1 activity, because geldanamycin, a Hsp90 inhibitor and an inducer of the heat shock response, caused a reduction of HIF-1 levels and its downstream transcriptional activity by accelerating protein degradation independent of O2 tens…”
BackgroundZhang, M.-X., Zhang, L., Fu, L., Yao, H., Tan, L., Feng, Z., Li, J., Lu, J. K., Pan, Y., Shu, G., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01971-7 · Cited by 52
Tumor-Intrinsic and Tumor-Extrinsic Factors Impacting Hsp90- Targeted Therapy
Alarcon, S., Mollapour, M., Lee, M.-J., Tsutsumi, S., Lee, S., Kim, Y. S., Prince, T. L., Apolo, A. B., Giaccone, G., Xu, W., et al. (2012) · Current Molecular Medicine · doi:10.2174/156652412803306729 · Cited by 49
Self-citationGe, Y., Yoon, S.-H., Jang, H., Jeong, J.-H., & Lee, Y.-M. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153318 · Cited by 49
Regulation of ROS Production and Vascular Function by Carbon Monoxide
Choi, Y. K., Por, E. D., Kwon, Y., & Kim, Y. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/794237 · Cited by 54
From Nf1 to Sdhb knockout: Successes and failures in the quest for animal models of pheochromocytoma
Lussey‐Lepoutre, C., Thibault, C., Buffet, A., Morin, A., Badoual, C., Bénit, P., Rustin, P., Ottolenghi, C., Janin, M., Castro‐Vega, L. J., et al. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.06.027 · Cited by 58
“It was reported that HSP90 binds HIF1 and participates to its stabilization (Isaacs et al., 2002).”
Jones, D. T., Pugh, C. W., Wigfield, S., Stevens, M. F. G., & Harris, A. L. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2380 · Cited by 48
“Previous studies have also shown that HIF-1a can coimmunoprecipitate with Hsp90/Hsp70 and that Hsp70 directly binds to the oxygen-dependent degradation domain of HIF-1a (48), so it is possible that Hsp70 directly stabilizes HIF-a and inhibit degradation of HIF-a through a pVHLindependent pathway ( 49 ), but this would…”
BackgroundJafari, A., Rezaei–Tavirani, M., Farhadihosseinabadi, B., Taranejoo, S., & Zali, H. (2020) · Cancer Investigation · doi:10.1080/07357907.2020.1752227 · Cited by 49
“prevents proteasome degradation of HIF1a, which in turn stimulates the activity of the HIF1 transcription factor (68,69).”
BackgroundMartínez, A., Zudaire, E., Portal‐Núñez, S., Guédez, L., Libutti, S. K., Stetler‐Stevenson, W. G., & Cuttitta, F. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0103 · Cited by 53
Self-citationIOP1, a novel hydrogenase-like protein that modulates hypoxia-inducible factor-1α activity
Huang, J., Song, D., Flores, A., Zhao, Q., Mooney, S. M., Shaw, L. M., & Lee, F. S. (2007) · Biochemical Journal · doi:10.1042/bj20060635 · Cited by 46
Lee, S.-C., Min, H., Choi, H., Kim, H. S., Kim, K.-C., Park, S., Seong, M. A., Seo, J. H., Park, H., Suh, Y., et al. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.096883 · Cited by 45
“…results showing that deguelin blocks Hsp90 function by directly binding to the ATP-binding pocket of Hsp90, resulting in the degradation of various client proteins, including HIF-1a (Isaacs et al., 2002; Oh et al., 2007), we assessed whether Hsp90 was involved in L80-mediated anticancer activity.”
BackgroundGan, E. S., & Ooi, E. E. (2020) · Virology Journal · doi:10.1186/s12985-020-01374-2 · Cited by 49
Hypoxia-Inducible Factor 1-Related Diseases and Prospective Therapeutic Tools
Park, J., Chun, Y., & Kim, M. (2004) · Journal of Pharmacological Sciences · doi:10.1254/jphs.94.221 · Cited by 49
Casillas, A. L., Chauhan, S. S., Toth, R. K., Sainz, A. G., Clements, A. N., Jensen, C. C., Langlais, P. R., Miranti, C. K., Cress, A. E., & Warfel, N. A. (2021) · Oncogene · doi:10.1038/s41388-021-01915-1 · Cited by 44
Wang, Y., Liu, X., Huang, W., Liang, J., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108303 · Cited by 46
Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015)
Ban, H. S., Uto, Y., Won, M., & Nakamura, H. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1146252 · Cited by 44
Sadaghianloo, N., Contenti, J., Dardik, A., & Mazure, N. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215387 · Cited by 48
Molecular Insights Into Lysyl Oxidases in Cartilage Regeneration and Rejuvenation
Lin, W., Xu, L., & Li, G. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00359 · Cited by 50
“…as heat shock protein 90, HSP90), and specific targeting of certain transcriptional activation of certain HIF-1 target genes (Minet et al., 1999; Isaacs et al., 2002; Katschinski et al., 2004), as well as regulation of systemic copper metabolism are promising Frontiers in Bioengineering and…”
BackgroundTibetan PHD2 , an allele with loss-of-function properties
Song, D., Navalsky, B. E., Guan, W., Ingersoll, C., Wang, T., Loro, E., Eeles, L., Matchett, K. B., Percy, M. J., Walsby-Tickle, J., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920546117 · Cited by 58
Induction of the Hypoxia-Inducible Factor System by Low Levels of Heat Shock Protein 90 Inhibitors
Ibrahim, N. O., Hahn, T., Franke, C., Stiehl, D. P., Wirthner, R., Wenger, R. H., & Katschinski, D. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1877 · Cited by 43
“To inhibit the HIF system, doses in the micromolar range have usually been used (17, 18 , 21, 22).”
MethodResultModification of the tumor microenvironment to enhance immunity
Liao, Y., Schaue, D., & McBride, W. H. (2007) · Frontiers in bioscience · doi:10.2741/2336 · Cited by 49
Pham, T. H., Lecomte, S., Efstathiou, T., Ferrière, F., & Pakdel, F. (2019) · Nutrients · doi:10.3390/nu11010079 · Cited by 48
Nigim, F., Cavanaugh, J., Patel, A. P., Curry, W. T., Esaki, S., Kasper, E. M., Chi, A. S., Louis, D. N., Martuza, R. L., Rabkin, S. D., et al. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000210 · Cited by 48
Sarkar, R., Mukherjee, S., Biswas, J., & Roy, M. (2015) · Free Radical Research · doi:10.3109/10715762.2015.1108520 · Cited by 43
García-Pastor, C., Martínez, S. B., Moreno‐Manzano, V., Fernández‐Martínez, A. B., & Lucio-Cazaña, F. J. (2019) · Scientific Reports · doi:10.1038/s41598-019-52310-6 · Cited by 46
Unlocking mammalian regeneration through hypoxia inducible factor one alpha signaling
DeFrates, K. G., Franco, D., Heber‐Katz, E., & Messersmith, P. B. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120646 · Cited by 44
“This has been shown to prevent HIF-1α ubiquitination and degradation in both normoxia and hypoxia [232, 233].”
BackgroundJain, K., Suryakumar, G., Prasad, R., & Ganju, L. (2013) · High Altitude Medicine & Biology · doi:10.1089/ham.2012.1064 · Cited by 47
“While HSP60 has previously been shown to play an antiapoptotic role in myocardial injury (Kirchhoff et al., 2002), HSP90 was recognized as a regulator of HIF-1 a stability (Minet et al., 1999; Isaacs et al., 2002).”
Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 - 2010)
Ban, H. S., Uto, Y., & Nakamura, H. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.547477 · Cited by 42
Inhibition of the hypoxia-inducible factor pathway by a G-quadruplex binding small molecule
Welsh, S. J., Dale, A. G., Lombardo, C. M., Valentine, H., de la Fuente, M., Schätzlein, A. G., & Neidle, S. (2013) · Scientific Reports · doi:10.1038/srep02799 · Cited by 42
CK2 and the Hallmarks of Cancer
Firnau, M.-B., & Brieger, A. (2022) · Biomedicines · doi:10.3390/biomedicines10081987 · Cited by 44
Marine natural products as inhibitors of hypoxic signaling in tumors
Nagle, D. G., & Zhou, Y. (2009) · Phytochemistry Reviews · doi:10.1007/s11101-009-9120-1 · Cited by 49
“Recent studies have implicated other oxygen-independent pathways that also regulate HIF-1a degradation (Isaacs et al. 2002; Liu et al. 2007a).”
Zhou, W., Dosey, T. L., Biechele, T. L., Moon, R. T., Horwitz, M. S., & Ruohola‐Baker, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027460 · Cited by 48
CHC promotes tumor growth and angiogenesis through regulation of HIF-1α and VEGF signaling
Tung, K.-H., Lin, C. W., Kuo, C. C., Li, L.-T., Kuo, Y.-H., Lin, C.-W., & Wu, H. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.12.001 · Cited by 41
“HIF-1a protein degradation has been reported to lead to a decrease in the transcription of HIF-1a down-stream genes [43–45].”
BackgroundNur77 upregulates HIF-α by inhibiting pVHL-mediated degradation
Kim, B.-Y., Kim, H., Cho, E., & Youn, H. (2008) · Experimental & Molecular Medicine · doi:10.3858/emm.2008.40.1.71 · Cited by 43
The Role of the Protein Quality Control System in SBMA
Rusmini, P., Crippa, V., Cristofani, R., Rinaldi, C., Cicardi, M. E., Galbiati, M., Carra, S., Malik, B., Greensmith, L., & Poletti, A. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0675-6 · Cited by 40
“VEGF is regulated by the HIF1A transcription factor, and as HIF1A has been shown to interact with HSPs (Huang et al. 2009; Isaacs et al. 2002), this may provide an explanation for the upregulation induced by arimoclomol.”
BackgroundWang, L., Liu, P., Wan, Z. Y., Huang, S. Q., Wen, Y. F., Lin, G., & Yue, G. H. (2016) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2016.06.058 · Cited by 40
The functional interplay between the HIF pathway and the ubiquitin system – more than a one-way road
Günter, J., Ruiz‐Serrano, A., Pickel, C., Wenger, R. H., & Scholz, C. C. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.03.027 · Cited by 41
Hypoxia-Inducible Factor (HIF): Fuel for Cancer Progression
Satija, S., Kaur, H., Tambuwala, M. M., Sharma, P., Vyas, M., Khurana, N., Sharma, N., Bakshi, H. A., Charbe, N. B., Zacconi, F. C. M., et al. (2021) · Current Molecular Pharmacology · doi:10.2174/1874467214666210120154929 · Cited by 40
Greish, K. F., Ray, A., Bauer, H., Larson, N., Malugin, A., Pike, D. B., Haider, M. A., & Ghandehari, H. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.12.015 · Cited by 41
“GDM derivatives have shown to inhibit Hsp90 mediated activation, stability, and function of HIF-1α [11,12].”
BackgroundLee, J. M., Lee, W. H., Kay, H. Y., Kim, E., Moon, A., & Kim, S. G. (2011) · International Journal of Cancer · doi:10.1002/ijc.26075 · Cited by 42
The metal-responsive transcription factor-1 contributes to HIF-1 activation during hypoxic stress
Murphy, B. J., Sato, B., Dalton, T. P., & Laderoute, K. R. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.124 · Cited by 41
Mechanisms of Disease: the role of heat-shock protein 90 in genitourinary malignancy
Lattouf, J., Srinivasan, R., Pinto, P. A., Linehan, W. M., & Neckers, L. Μ. (2006) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0604 · Cited by 44
Self-citationBile acids destabilise HIF-1α and promote anti-tumour phenotypes in cancer cell models
Phelan, J. P., Reen, F. J., Dunphy, N., O’Connor, R., & O’Gara, F. (2016) · BMC Cancer · doi:10.1186/s12885-016-2528-2 · Cited by 40
“Many chemical and molecular inhibitors have been developed to destabilise HIF-1α [26–28], however, many have not progressed to clinical trials due to nonspecificity and cytotoxicity issues [29].”
Thymoquinone Selectively Kills Hypoxic Renal Cancer Cells by Suppressing HIF-1α-Mediated Glycolysis
Lee, Y.-M., Kim, G.-H., Park, E. J., Oh, T.-I., Lee, S., Kan, S.-Y., Kang, H., Kim, B. M., Kim, J. H., & Lim, J.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051092 · Cited by 43
Hypoxia‐Inducible Factor 1 Inhibitors
Melillo, G. (2007) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)35020-9 · Cited by 44
Izquierdo-Álvarez, A., Ramos, E. M., Villanueva, J., Hernansanz‐Agustín, P., Fernández‐Rodríguez, R., Tello, D., Carrascal, M., & Martínez-Ruiz, A. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.06.035 · Cited by 39
HAF: The new player in oxygen-independent HIF-1α degradation
Koh, M. Y., & Powis, G. (2009) · Cell Cycle · doi:10.4161/cc.8.9.8303 · Cited by 52
Effects of geldanamycin on HIF-1α mediated angiogenesis and invasion in prostate cancer cells
Alqawi, O., Moghaddas, M., & Singh, G. (2006) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500852 · Cited by 40
Wu, W., Kao, Y. H., Hu, P., & Chen, J.-H. (2007) · Experimental Eye Research · doi:10.1016/j.exer.2007.08.005 · Cited by 41
Proceedings of the Oxygen Homeostasis/Hypoxia Meeting
Kaufman, B., Scharf, O., Arbeit, J., Ashcroft, M., Brown, J. M., Bruick, R. K., Chapman, J. D., Evans, S. M., Giaccia, A. J., Harris, A. L., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2611 · Cited by 38
“Geldanamycin promotes the down-regulation of HIF-1 and inhibits its transcriptional activity (56, 57).”
BackgroundSelf-citationInhibition of HSP90 could be possible mechanism for anti-cancer property of amniotic membrane
Niknejad, H., Yazdanpanah, G., Mirmasoumi, M., Abolghasemi, H., Peirovi, H., & Ahmadiani, A. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.08.018 · Cited by 39
Levesque, K., Wright, P. A., & Bernier, N. J. (2019) · Physiological and Biochemical Zoology · doi:10.1086/703178 · Cited by 36
Choi, D., Han, J., Lee, Y., Choi, J., Han, S.-Y., Hong, S., Jeon, H., Kim, Y. M., & Jung, Y. (2009) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.06.002 · Cited by 40
Self-citationLeu-574 of HIF-1α Is Essential for the von Hippel-Lindau (VHL)-mediated Degradation Pathway
Huang, L. E., Pete, E. A., Schau, M., Milligan, J., & Gu, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207280200 · Cited by 37
Exploration of the HIF-1α/p300 interface using peptide and Adhiron phage display technologies
Kyle, H. F., Wickson, K. F., Stott, J., Burslem, G. M., Breeze, A. L., Tiede, C., Tomlinson, D. C., Warriner, S. L., Nelson, A. S., Wilson, A. J., et al. (2015) · Molecular BioSystems · doi:10.1039/c5mb00284b · Cited by 42
Sceneay, J., Liu, M. C. P., Chen, A., Wong, C. S. F., Bowtell, D. D. L., & Möller, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066388 · Cited by 38
Thioredoxin-1 redox signaling regulates cell survival in response to hyperoxia
Floen, M. J., Forred, B. J., Bloom, E., & Vitiello, P. F. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.07.023 · Cited by 38
Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma
Vícha, A., Taïeb, D., & Pacák, K. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0398 · Cited by 37
“Thus, inhibitors of HSP90, such as geldanamycin, and analogs, such as 17-allylamino geldanamycin (17-AAG; tanespimycin), 17-dimethylaminoethylamino- 17-demethoxygeldanamycin (alespimicin), or other new analogs, are promising therapeutic agents (Isaacs et al. 2002, Northcott et al. 2012).”
Sharma, N. M., Cunningham, C., Zheng, H., Liu, X., & Patel, K. P. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.003423 · Cited by 38
Mohindra, V., Tripathi, R. K., Yadav, P., Singh, R. K., & LAL, K. K. (2015) · Molecular Biology Reports · doi:10.1007/s11033-015-3855-0 · Cited by 36
Ubiquitin domain proteins in disease
Madsen, L., Schulze, A., Seeger, M., & Hartmann‐Petersen, R. (2007) · BMC Biochemistry · doi:10.1186/1471-2091-8-s1-s1 · Cited by 36
Editorial: Molecular Targeting of VHL Gene Pathway in Clear Cell Kidney Cancer
Linehan, W. M. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000077210.05543.ae · Cited by 36
Sun, P., Lu, Y., Cheng, D., Zhang, K., Zheng, J., Liu, Y., Wang, X., Yuan, Y., & Tang, Y. (2018) · Hepatology · doi:10.1002/hep.30086 · Cited by 34
The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia
Gallez, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.853568 · Cited by 37
“Other small molecules used in clinical trials such as the Hsp90 inhibitors geldanamycin and tanespimycin (17-AAG) have been shown to promote HIFα degradation (Isaacs et al., 2002; Mabjeesh et al., 2002; Neckers, 2002; Alqawi et al., 2006; Cao et al., 2008).”
BackgroundHan, J., Lee, J.-S., Choi, D., Lee, Y., Hong, S., Choi, J., Han, S.-Y., Ko, Y., Kim, J., & Kim, Y. M. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.01.003 · Cited by 36
HSP90: A Rising Star on the Horizon of Anticancer Targets
Whitesell, L. J., & Dai, C. (2005) · Future Oncology · doi:10.2217/14796694.1.4.529 · Cited by 40
Combinatorial Antitumor Effect of Naringenin and Curcumin Elicit Angioinhibitory Activities In Vivo
Anand, K., Sarkar, A., Kumar, A., Ambasta, R. K., & Kumar, P. (2012) · Nutrition and Cancer · doi:10.1080/01635581.2012.686648 · Cited by 34
“In this report, we have shown that CUR and NGEN together inhibit the Hsp90 expression that plays a critical role in the stabilization of several client proteins implicated in the control of cell growth and malignant transformation ( 29 – 31 , 46 , 47 ).”
BackgroundFunctional regulation of hypoxia inducible factor-1α by SET9 lysine methyltransferase
Liu, Q., Geng, H., Xue, C., Beer, T. M., & Qian, D. Z. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.01.011 · Cited by 35
“For example, RACK1 competes with the chaperon HSP90 and promotes HIF-1α degradation [13,14], HSP70 and the ubiquitin E3 ligase CHIP promote ubiquitin proteasomal degradation of HIF-1α [15].”
BackgroundARDent about acetylation and deacetylation in hypoxia signalling
Bilton, R. L., Trottier, E., Pouysségur, J., & Brahimi-Horn, M. C. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.10.002 · Cited by 34
Bohonowych, J. E., Peng, S., Gopal, U., Hance, M. W., Wing, S. B., Argraves, K. M., Lundgren, K., & Isaacs, J. S. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-520 · Cited by 32
“To confirm that EC154 and LBH589 similarly maintain efficacy under hypoxia, UMCRC2 and 786-O cells were exposed to hypoxia [25,71] for 16 h in either the presence or absence of these agents.”
BackgroundMethodResultSelf-citationBenzo[a]pyrene-3,6-dione inhibited VEGF expression through inducing HIF-1α degradation
Li, Z., Liu, L.-Z., Shi, X., Fang, J. S., & Jiang, B. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.03.178 · Cited by 34
Han, S. Y., Ko, A., Kitano, H., Choi, C. H., Lee, M.-S., Seo, J., Fukuoka, J., Kim, S.-Y., Hewitt, S. M., Chung, J.-Y., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0613 · Cited by 32
Hypoxia as a physiological cue and pathological stress for coral larvae
Alderdice, R., Pernice, M., Cárdenas, A., Hughes, D. J., Harrison, P. L., Boulotte, N., Chartrand, K., Kühl, M., Suggett, D. J., & Voolstra, C. R. (2021) · Molecular Ecology · doi:10.1111/mec.16259 · Cited by 37
Hypoxia Inducible Factor pathway proteins in high-altitude mammals
Lee, F. S. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2023.11.002 · Cited by 32
Hypoxia-inducible factors: Crosstalk between their protein stability and protein degradation
Wei, W., & Yu, X. D. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.08.009 · Cited by 34
Exploitation of the HIF axis for cancer therapy
Escuín, D., Simons, J. W., & Giannakakou, P. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.7.954 · Cited by 32
Role of the ubiquitin proteasome system in renal cell carcinoma
Corn, P. G. (2007) · BMC Biochemistry · doi:10.1186/1471-2091-8-s1-s4 · Cited by 40
HDAC6 regulates sensitivity to cell death in response to stress and post-stress recovery
Ryu, H.-W., Won, H.-R., Lee, D. H., & Kwon, S. H. (2017) · Cell Stress and Chaperones · doi:10.1007/s12192-017-0763-3 · Cited by 32
Schilling, D., Bayer, C., Li, W., Molls, M., Vaupel, P. W., & Multhoff, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031110 · Cited by 34
Platelet activation during tumor development, the potential role of BDNF–TrkB autocrine loop
Yang, Z. F., Ho, D. W., Lau, C. K., Tam, K. H., Lam, C. T., Poon, R. T. P., & Fan, S. T. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.06.007 · Cited by 30
King, M. J., Bukantz, S. C., Phillips, S. E., Mohapatra, S. S., Tamulis, T., & Lockey, R. F. (2004) · PubMed · Cited by 34
Feng, J., Xie, G., Zhan, Y., Lu, J., Xu, L., Fan, S., & Wang, W. (2019) · Histopathology · doi:10.1111/his.13862 · Cited by 30
Anti-Cancer Activity of Phytochemicals Targeting Hypoxia-Inducible Factor-1 Alpha
Yun, B. D., Son, S. W., Choi, S. Y., Kuh, H. J., Oh, T., & Park, J. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189819 · Cited by 35
Metadata
- Authors
- Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M.
- Affiliations
- National Institutes of Health (US)
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2002-08
- Volume
- 277
- Issue
- 33
- Pages
- 29936-29944
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2022471909
- Cited by
- 663
- References
- 81
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 10 · 2023: 19 · 2022: 22 · 2021: 32 · 2020: 19 · 2019: 20 · 2018: 19 · 2017: 20 · 2016: 22 · 2015: 30 · 2014: 31 · 2013: 27 · 2012: 41
- FWCI
- 13.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6667 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HSP90, HIF-1α, VHL, hypoxia, protein degradation, geldanamycin, E3 ubiquitin ligase, proteasome, renal carcinoma, angiogenesis, vascular endothelial growth factor, anti-angiogenic therapy, hypoxic cell radiosensitizers
- MeSH terms
- Cysteine Endopeptidases, Hydrolysis, Ligases, Multienzyme Complexes, Transcription Factors, Transcription, Genetic, Tumor Cells, Cultured, Down-Regulation, HSP90 Heat-Shock Proteins, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Proteasome Endopeptidase Complex, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.